Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report

被引：0

作者：

Pinto, Catarina ^{[1
]}

Bergmann, Michael ^{[2
]}

Briukhovetska, Daria ^{[3
,4
]}

Nuessler, Volkmar ^{[3
,4
,5
]}

Sznol, Mario ^{[6
]}

von Bergwelt-Baildon, Michael ^{[7
,8
]}

Kobold, Sebastian ^{[3
,4
,8
]}

机构：

[1] Boehringer Ingelheim RCV GmbH & Co KG, Human Canc Immunol, Vienna, Austria

[2] Med Univ Vienna, Dept Surg, Vienna, Austria

[3] Klinikum Ludwig Maximilians Univ Munchen, Ctr Integrated Prot Sci Munich CIPS M, Munich, Germany

[4] Klinikum Ludwig Maximilians Univ Munchen, Div Clin Pharmacol, Munich, Germany

[5] Tumor Ctr Munich, Munich, Germany

[6] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[7] Klinikum Ludwig Maximilians Univ Munchen, Dept Med 3, Munich, Germany

[8] German Consortium Translat Canc Res DKTK, Munich, Germany

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷 / 01期

基金：

欧洲研究理事会; 欧盟地平线“2020”;

关键词：

immunology; tumours; IMMUNO-ONCOLOGY;

D O I：

10.1136/jitc-2019-000268

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapy has moved to the forefront of cancer treatment, illustrated by the accelerating pace of novel therapy approvals. In this complex environment, scientists rely on cutting edge conferences to stay informed. The Immunotherapy of Cancer (ITOC) conference was established jointly with the Society of the Immunotherapy of Cancer to bring the European researchers together. In its sixth edition, the ITOC conference has recently been held in Vienna, Austria.

引用

页数：4